BiotoxtechCo.,Ltd.

086040KOSDAQResearch and development

BiotoxtechCo.,Ltd. (086040, KOSDAQ) reported KRW 47bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202333-8-914748Consolidated
202441-9-1313635Consolidated
202547-5-213232Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-25.1%-27.4%32.8%-18.6%
2024-21.5%-30.6%25.4%-36.7%
2025-10.2%-3.3%24.3%-4.9%

Revenue moved 44.1% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 37bn
Close priceKRW 2,330
Listed shares15,958,247
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)241
Women131 (54.4%)
Average tenure3.5 years
Annual pay, menKRW 46,418,182
Annual pay, womenKRW 47,534,351
Pay ratio, women to men102.4%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →